Critical Survey: Artiva Biotherapeutics (ARTV) vs. Its Peers

Artiva Biotherapeutics (NASDAQ:ARTV) is one of 616 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its competitors? We will compare Artiva Biotherapeutics to related companies based on the strength of its analyst recommendations, profitability, risk, institutional ownership, valuation, earnings and dividends.

Valuation & Earnings

This table compares Artiva Biotherapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Artiva Biotherapeutics	$250,000.00	-$65.37 million	-1.55
Artiva Biotherapeutics Competitors	$994.30 million	$76.94 million	8.08

Artiva Biotherapeutics’ competitors have higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Artiva Biotherapeutics has a beta of 2.92, indicating that its share price is 192% more volatile than the S&P 500. Comparatively, Artiva Biotherapeutics’ competitors have a beta of 1.03, indicating that their average share price is 3% more volatile than the S&P 500.

Profitability

This table compares Artiva Biotherapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-49.99%	-44.05%
Artiva Biotherapeutics Competitors	-910.50%	-116.60%	-28.78%

Institutional & Insider Ownership

51.3% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by company insiders. Comparatively, 13.2% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Artiva Biotherapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1	0	4	1	2.83
Artiva Biotherapeutics Competitors	7412	12757	38846	1251	2.56

Artiva Biotherapeutics currently has a consensus price target of $19.00, suggesting a potential upside of 375.00%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 64.30%. Given Artiva Biotherapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Artiva Biotherapeutics is more favorable than its competitors.

Summary

Artiva Biotherapeutics beats its competitors on 8 of the 13 factors compared.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.